The U.S. IPO market is gaining momentum, with several issuers set for this week. Notably, defense contractor Karman Space & ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, potentially, more common obesity-related conditions.

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following a $94M initial public offering. Read more here.

Clinical-stage biopharmaceutical company Aardvark Therapeutics (AARD) priced its IPO of ~5.89M shares at $16.00 per share. All of the shares are being offered by Aardvark. The California-based startup ...

While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

Aardvark Wine Lounge, 304 Pine St., in Green Bay opened Jan. 6, 2017 and will officially close on Feb. 21, according to a ...

Aardvark Therapeutics, Inc. ("Aardvark") (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...

A group of young singer-songwriters have transformed the genre by looking backward, without getting stuck in the past.